Some cancer cells that become tolerant to a drug remain resistant even after its withdrawal, yet these cells eventually become sensitive to the drug again. The underlying molecular mechanism is unusual.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nowell, P. C. Science 194, 23–28 (1976).
Weinberg, R. A. The Biology of Cancer Ch. 11 (Garland Science, 2006).
Stratton, M. R. et al. Nature 458, 719–724 (2009).
Vogelstein, B. et al. N. Engl. J. Med. 319, 525–532 (1988).
Hanahan, D. & Weinberg, R. A. Cell 100, 57–70 (2000).
Greaves, M. Hematology 3–12 (2009).
Sawyers, C. L. Nature Med. 13, 1144–1145 (2007).
Redmond, K. M. et al. Front. Biosci. 13, 5138–5154 (2008).
Sharma, S. V. et al. Cell 141, 69–80 (2010).
Benevolenskaya, E. V. et al. Mol. Cell 18, 623–635 (2005).
Dhar, N. & McKinney J. D. Curr. Opin. Microbiol. 10, 30–38 (2007).
Cara, S. & Tannock, I. F. Ann. Oncol. 12, 23–27 (2001).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Paul Workman is an employee of and Jon Travers a graduate student at the Institute of Cancer Research (ICR), which operates a rewards to inventors scheme. The ICR has an actual or potential commercial interest in inhibitors of chromatin-modifying enzymes, including histone deacetylases and histone demethylases. P.W. is a founder of, Scientific Advisory Board chair of, consultant to, non-executive director of and member of the Board of Directors of Chroma Therapeutics.
Rights and permissions
About this article
Cite this article
Workman, P., Travers, J. Drug-tolerant insurgents. Nature 464, 844–845 (2010). https://doi.org/10.1038/464844a
Published:
Issue Date:
DOI: https://doi.org/10.1038/464844a
This article is cited by
-
Envisioning the future of early anticancer drug development
Nature Reviews Cancer (2010)